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ABSTRACT
Background COVID-19 has become the most 
common cause of acute respiratory distress syndrome 
(ARDS) worldwide. Features of the pathophysiology 
and clinical presentation partially distinguish it from 
’classical’ ARDS. A Research and Development (RAND) 
analysis gauged the opinion of an expert panel about 
the management of ARDS with and without COVID-19 
as the precipitating cause, using recent UK guidelines 
as a template.
Methods An 11- person panel comprising intensive 
care practitioners rated the appropriateness of ARDS 
management options at different times during hospital 
admission, in the presence or absence of, or varying 
severity of SARS- CoV-2 infection on a scale of 1–9 
(where 1–3 is inappropriate, 4–6 is uncertain and 
7–9 is appropriate). A summary of the anonymised 
results was discussed at an online meeting moderated 
by an expert in RAND methodology. The modified 
online survey comprising 76 questions, subdivided 
into investigations (16), non- invasive respiratory 
support (18), basic intensive care unit management 
of ARDS (20), management of refractory hypoxaemia 
(8), pharmacotherapy (7) and anticoagulation (7), was 
completed again.
Results Disagreement between experts was significant 
only when addressing the appropriateness of diagnostic 
bronchoscopy in patients with confirmed or suspected 
COVID-19. Adherence to existing published guidelines 
for the management of ARDS for relevant evidence- 
based interventions was recommended. Responses of the 
experts to the final survey suggested that the supportive 
management of ARDS should be the same, regardless 
of a COVID-19 diagnosis. For patients with ARDS with 
COVID-19, the panel recommended routine treatment 
with corticosteroids and a lower threshold for full 
anticoagulation based on a high index of suspicion for 
venous thromboembolic disease.
Conclusion The expert panel found no reason to 
deviate from the evidence- based supportive strategies for 
managing ARDS outlined in recent guidelines.
INTRODUCTION
To date, SARS- CoV-2 has infected over 66 million 
people, causing more than 1.5 million deaths 
worldwide.1 The associated COVID-19 pandemic 
precipitated a wave of critically ill patients that 
overwhelmed mature as well as developing health-
care systems in multiple hot spots across the world. 
For example, the Office for National Statistics 
reports that since the start of the pandemic, there 
have been 63 852 COVID-19 deaths registered 
in England and Wales, up to 20 November 2020 
(35 358 men and 28 494 women), which almost 
certainly underestimates the actual death toll.2
The most common cause of hospitalisation for 
patients with COVID-19 was acute respiratory 
Key messages
What is the key question?
 ► Acute respiratory distress syndrome (ARDS) 
guidelines are based on trials that predate 
the COVID-19 pandemic, raising the question 
that alternative management strategies may 
be appropriate for COVID-19- associated ARDS 
which manifests some distinct pathophysiology 
and clinical features.
What is the bottom line?
 ► While specific disease- modifying treatments 
for COVID-19 are rapidly emerging, the basic 
supportive management of respiratory failure 
should follow existing ARDS guidelines.
Why read on?
 ► A Research and Development/ University of 
California Los Angeles (RAND/UCLA) panel 
judged the appropriateness in the management 
of ARDS associated with COVID-19 and ARDS 
that was not COVID-19- related of interventions 
recommended in guidelines and other 
commonly used management strategies where 
the evidence base is lacking.
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failure associated with viral pneumonia and sepsis syndrome, 
ultimately leading to acute respiratory distress syndrome 
(ARDS). A high proportion of these patients required respira-
tory support ranging from non- invasive and invasive mechanical 
ventilation to extracorporeal membrane oxygenation (ECMO). 
COVID-19- associated strain on health resource capacity high-
lighted the need to optimise the management of patients with 
ARDS, including those with mild ARDS, a category where the 
diagnosis is frequently missed.3 Similarly, COVID-19- related 
ARDS is associated with a high mortality and prolonged length 
of intensive care unit (ICU) and hospital stay.4 In addition, long- 
term follow- up studies of patients with ARDS have indicated 
high long- term loss of quality of life and employment.5
Although related to other coronaviruses that cause ARDS, 
SARS- CoV-2 infection was associated with a novel constellation 
of clinical features and distinct pathophysiology, for example, a 
high incidence of intravascular thrombosis.6 Hence, the question 
of whether this is ‘normal’ ARDS or a distinct syndrome with 
correspondingly different management has been debated.7 At 
the same time, a plethora of pronouncements on social media, 
multiple case series and some data from large platform studies 
and clinical trials have emerged. For example, non- invasive 
respiratory support strategies, including continuous positive 
airway pressure (CPAP) or high- flow nasal oxygen (HFNO), 
might provide sufficient support in some patients, obviating 
the need for invasive mechanical ventilation. However, these 
interventions may also cause harm, such as ventilator- associated 
lung injury (VALI), delay to invasive mechanical ventilation and 
exposure of a healthcare worker to COVID-19- laden aerosols. 
Uncertainty about the optimal approach to non- invasive respira-
tory support in COVID-19 has been reflected in variation in the 
recommendations of international guidelines and clinical prac-
tice.8–12 Accordingly, in the context of the COVID-19 pandemic, 
the applicability of current international guidelines for the 
management of ARDS has been questioned.7
In 2018–2019, the UK Faculty of Intensive Care Medicine 
(FICM) and Intensive Care Society (ICS) produced a guideline 
using Grading of Recommendations Assessment, Development 
and Evaluation methodology13 for the management of ARDS in 
adult patients that was adopted by the British Thoracic Society, 
henceforth referred to as the ‘UK guideline’.14 The recommen-
dations of the UK guideline were broadly consistent with the 
American Thoracic Society/European Society of Intensive Care 
Medicine/Society of Critical Care Medicine clinical practice 
guidelines 2017 for patients with ARDS,15 which considered 
6 of the 10 interventions considered by the UK group. Here, 
Research and Development/University of California Los Angeles 
(RAND/UCLA) Appropriateness Methodology was used to 
determine whether a multidisciplinary panel of experts from the 
UK were in favour of adhering to recommendations in the UK 
guideline for patients with COVID-19- associated ARDS. Assess-
ment was also made of the appropriateness of other interven-
tions that were either outside the scope of the ARDS guidelines 
or had been suggested during the COVID-19 pandemic.
METHODS
The RAND/UCLA appropriateness method uses a modified 
Delphi panel approach, thereby combining expert opinion 
with the best available evidence to determine the appropriate-
ness of specific practices in defined clinical situations.16 Using 
this method to score appropriateness is validated as a means of 
determining the benefit versus harm of a given intervention irre-
spective of the cost or resources. It is particularly useful in areas 
of uncertainty in which evidence is insufficient to guide clinical 
practice, such as in the COVID-19 pandemic.17
The aim of this RAND panel was to provide expert opinion 
on the appropriateness of various interventions used in the 
management of ARDS, as defined using the Berlin criteria,3 in 
the context of the COVID-19 pandemic. The questionnaire 
sought to identify areas where it was appropriate to deviate from 
current guidelines for the management of ARDS in adult patients 
in the context of the COVID-19 pandemic, as well as addressing 
interventions that for various reasons are not part of existing 
guidelines. Where there was an acceptably low level of disparity, 
a corresponding recommendation was made about the routine 
use of the intervention in question.
The expert panel comprised intensive care practitioners from 
various professional groups and centres across the UK. Of the 16 
experts who were originally invited, 2 declined because they felt 
that they had inadequate knowledge and 3 were unexpectedly 
unable to dial into the discussion panel meeting. The 11 remaining 
experts are listed in online supplemental table 1. A bibliography 
of references (online supplemental file 1) on the management of 
ARDS and COVID-19 published after the ICS UK guideline on 
the management of ARDS in adults14 was sent to the expert panel 
with an invitation to a web- based questionnaire. The questionnaire 
was completed prior to an online meeting moderated by an expert 
in RAND methodology (PMI). Panellists rated the appropriateness 
of management options at different times during hospital admis-
sion for ARDS in the presence or absence of, or varying severity of 
SARS- CoV-2 infection. They were asked to grade the appropriate-
ness of specific interventions on a scale of 1–9 (where 1–3 is inap-
propriate, 4–6 is uncertain and 7–9 is appropriate). The responses 
were summarised and anonymised before being presented at a 
virtual meeting in November 2020, which ensured a common 
understanding of the questions and focused on areas of disagree-
ment, without trying to force consensus. The moderators provided 
expertise in RAND methodology, but neither expressed opinions 
on management nor voted.
After the meeting, a second online survey comprising 76 
questions was completed. The second and final survey had been 
modified from the initial questionnaire following discussion at 
the meeting. Questions in the final survey were subdivided as 
follows: investigations (16), non- invasive respiratory support 
(18), basic ICU management of ARDS (20), management of 
refractory hypoxaemia (8), pharmacotherapy (7) and anticoag-
ulation (7).
Several assumptions were made. First, the diagnoses of ARDS 
and COVID-19 were assigned arbitrarily and absolutely. Second, 
other than those areas addressed in the survey, the management of 
ARDS was assumed to be in line with the UK guideline.14 Finally, 
care levels 2 and 3 (high dependency and critical care units) were 
defined by the Department of Health report ‘Comprehensive Crit-
ical Care’.18
For each scenario, median scores were calculated with a 
score of <3.5 being considered inappropriate, ≥3.5 and<6.5 
uncertain and ≥6.5 appropriate. We used the validated RAND 
disagreement index (DI) to define disagreement (DI ≥1) among 
panellists using the equation below.16 Any scenario in which 
disagreement was found was scored as uncertain, regardless of 
the median score.





= 70th−30th centile2.35+(1.5×abs(5−70th−30th centile/2)) 
where Abs is the absolute difference between the appropriate-
ness score given and the panel median expressed as a positive 
number.
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RESULTS
The final survey comprised 76 statements concerning the 
management of ARDS in adult patients with confirmed or 
suspected COVID-19 or patients with non- COVID-19- related 
ARDS: 35 were rated as appropriate, 33 as uncertain and 8 as 
inappropriate. Disagreement (DI>1) occurred in one scenario 
only. Online supplemental table 2 shows the RAND statements 
included in the final survey with associated median scores, DI 
and final appropriateness outcome category.
Investigations on admission to critical care of patients with 
confirmed or clinically suspected COVID-19 in the context 
of the pandemic versus those with respiratory failure or 
ARDS not associated with COVID-19 presenting outside the 
pandemic
It was deemed appropriate that all patients admitted to level 2 
or 3 care should have a full community- acquired pneumonia 
(CAP) microbiology screen and echocardiogram irrespective of 
the aetiology of the ARDS. Routine bronchoscopy in intubated 
patients was rated uncertain, irrespective of the ARDS aetiology. 
This was driven by significant levels of disagreement between 
panellists denoted by a DI of 1.04 in patients with COVID-19, 
despite a median score of 3, whereas in non- COVID-19 patients, 
it was due to a median score of 6. (table 1)
Routine CT of the thorax was deemed uncertain, irrespective 
of the ARDS aetiology, as was performing a routine autoimmune 
screen in COVID-19- related ARDS. By contrast, autoimmune 
screening was deemed appropriate in non- COVID-19 ARDS. 
The use of circulating biomarkers of syndromes resembling 
haemophagocytic lymphohistocytosis (such as lactate dehydro-
genase and ferritin), procalcitonin and troponin was deemed 
uncertain irrespective of the ARDS aetiology.
Use of non-invasive ventilatory strategies in patients with 
confirmed or clinically suspected COVID-19 in the context 
of the pandemic versus those with respiratory failure or 
ARDS not associated with COVID-19 presenting outside the 
pandemic
Irrespective of the aetiology and context of ARDS, the use of 
CPAP, nasal high- flow oxygen (NHFO) and awake proning was 
deemed to be of uncertain value. Non- invasive ventilation (NIV) 
was considered to be an inappropriate modality of respiratory 
support for all patients with ARDS regardless of the cause. 
Assessment of failure of non- invasive ventilatory strategies 1–4 
hours after initiation by the presence of unacceptable arterial 
blood gas, unacceptable work of breathing and the failure to 
improve were all deemed appropriate. Where first- line non- 
invasive strategies had failed, it was deemed inappropriate to 
trial an alternative non- invasive ventilatory strategy, but appro-
priate to proceed to tracheal intubation and invasive mechanical 
ventilation. Results were consistent irrespective of the patient’s 
COVID-19 status or pandemic context. (table 2)
Table 1 Investigations on admission to level 2 or 3 care
Time point
Investigations on admission to level 2 or 3 care (HDU or ITU)
Confirmed or suspected COVID-19* Non- COVID-19 ARDS†
Routinely on admission CAP screen Bronchoscopy‡ CAP screen Bronchoscopy§
Echocardiogram CT thorax±CTPA Echocardiogram CT thorax±CTPA
Autoimmune screen Autoimmune screen
Routinely on admission, repeated if 
clinically indicated
Procalcitonin Troponin Procalcitonin Troponin
Circulating biomarkers of HLH- like syndrome Circulating biomarkers of HLH- like syndrome
For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate (red background), ≥3.5 and <6.5 uncertain (amber background) 
and ≥6.5 appropriate (green background).
*In the context of the pandemic.
†Outside the context of the pandemic.
‡Denotes disagreement (disagreement index >1).
§Bronchoscopy if intubated.
ARDS, acute respiratory distress syndrome; CAP, community- acquired pneumonia (microbiology screen); CTPA, CT pulmonary angiogram; HDU, high dependency unit; HLH, 
haemophagocytic lymphohistiocytosis markers (ie, lactate dehydrogenase, ferritin); ITU, intensive therapy unit.
Table 2 Non- invasive ventilatory strategies
Intervention
Standard care: non- invasive ventilatory strategies
Confirmed or suspected COVID-19* Non- COVID-19 ARDS†




NHFO NIV NHFO NIV
CPAP Awake proning CPAP Awake proning
Indicators of failure of 
trial of non- invasive 
respiratory support
‘Unacceptable’ ABG ‘Unacceptable’ work 
of breathing
Failure to improve ‘Unacceptable’ ABG ‘Unacceptable’ work 
of breathing
Failure to improve
Trial of therapy after 
failure of first- line 
strategy
An alternative non- 
invasive strategy
Invasive mechanical ventilation An alternative non- 
invasive strategy
Invasive mechanical ventilation
For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate (red background), ≥3.5 and<6.5 uncertain (amber background) 
and ≥6.5 appropriate (green background).
*In the context of the pandemic.
†Outside the context of the pandemic.
ABG, arterial blood gas; ARDS, acute respiratory distress syndrome; CPAP, continuous positive airway pressure; NHFO, nasal high- flow oxygen; NIV, non- invasive ventilation.
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Basic management strategies in mechanically ventilated 
patients and adjuncts for refractory hypoxia with confirmed 
or clinically suspected COVID-19 in the context of the 
pandemic versus those with respiratory failure or ARDS not 
associated with COVID-19 presenting outside the pandemic
Lung- protective ventilation (defined as tidal volume <6 mL/
kg ideal body weight and plateau pressure <30 cmH20), prone 
positioning, use of higher end- expiratory pressure (PEEP) and 
conservative fluid management were all deemed appropriate 
irrespective of the context and aetiology of ARDS or time 
interval after intubation (defined as <48 hours or >48 hours). 
Continuous infusion of neuromuscular blocking agents was 
deemed uncertain irrespective of the time period considered or 
the aetiology of the ARDS. (table 3)
In patients with severe ARDS and refractory hypoxia, inhaled 
pulmonary vasodilators were deemed uncertain in COVID-
19- related ARDS but inappropriate in non- COVID-19- related 
ARDS. Regardless of the ARDS aetiology, recruitment manoeu-
vres were deemed inappropriate, airway pressure release venti-
lation (APRV) was uncertain, while referral to an ECMO centre 
was rated appropriate.
Pharmacotherapy and anticoagulation in patients with 
confirmed or suspected COVID-19 and established or 
incipient organ failure
A 10- day course of low- dose corticosteroids on admission was 
the only appropriate pharmacotherapy in this patient group. 
Most other treatments (standard course of antibiotics, remde-
sevir, inhibitors of the cytokine storm, late- phase steroids for 
failed weaning and pulmonary vasodilators) were deemed uncer-
tain, whereas antifibrotic therapy was deemed inappropriate. 
(table 4)
It was considered appropriate to prescribe standard throm-
boprophylaxis in all patients without contraindications, 
whereas the use of routine enhanced thromboprophylaxis, full 
anticoagulation and antiplatelet therapy were all considered 
uncertain. It was deemed appropriate to initiate full antico-
agulation for standard indications, including confirmed or 
suspected venous thromboembolic disease, whereas initiation 
of full anticoagulation based solely on a moderately raised 
D- dimer (≥4 times upper limit of normal) was considered 
uncertain.
Table 3 Basic management strategies in mechanically ventilated patients
Time point
Basic management strategies in mechanically ventilated patients
Confirmed or suspected COVID-19* Non- COVID-19 ARDS†
First 48 hours after intubation Lung- protective ventilation Prone positioning Lung- protective ventilation Prone positioning
Neuromuscular blocking agents Higher PEEP Neuromuscular blocking agents Higher Peep
Conservative fluid management Conservative fluid management
After the first 48 hours after 
intubation
Lung- protective ventilation Prone positioning Lung- protective ventilation Prone positioning
Neuromuscular blocking agents Higher PEEP Neuromuscular blocking agents Higher PEEP
Conservative fluid management Conservative fluid management
Severe ARDS and refractory 
hypoxia
Inhaled pulmonary vasodilators Recruitment manoeuvres Inhaled pulmonary vasodilators Recruitment manoeuvres
APRV ECMO APRV ECMO
For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate (red background), ≥3.5 and <6.5 uncertain (amber background) 
and ≥6.5 appropriate (green background).
*In the context of the pandemic.
†Outside the context of the pandemic.
APRV, airway pressure release ventilation; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation/referral to an ECMO centre; lung- protective 
ventilation, tidal volume <6 mL/kg ideal body weight and plateau pressure <30 cmH2O; PEEP, positive end- expiratory pressure.
Table 4 Pharmacotherapy and anticoagulation
Intervention
Pharmacotherapy
Confirmed or suspected COVID-19* and established or incipient organ failure(s)
Medical therapy Standard- course CAP antibiotics Low- dose corticosteroids on admission 
for 10 days
Late corticosteroids for failed 
weaning†
Antifibrotic therapy‡
Remdesevir Cytokine storm agents* Pulmonary vasodilators§   
All patients without 
contraindication to 
anticoagulation
Standard thromboprophylaxis Enhanced thromboprophylaxis Full anticoagulation Antiplatelet therapy
Indications for full 
anticoagulation
Standard indications Clinical suspicion of VTE Moderately raised D- dimer (≥4× 
ULN)
  
For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate (red background), ≥3.5 andb<6.5 uncertain (amber background) 
and ≥6.5 appropriate (green background).
*For example, tociluzimab.
†For example, intravenous methylprednisolone 2 mg/kg/day for 2–4 weeks.
‡For example, nintedanib for persistent respiratory failure with radiological evidence of lung fibrosis.
§For example, sildenafil for pulmonary hypertension or right ventricular failure; for example, nintedanib for persistent respiratory failure with radiological evidence of lung 
fibrosis.
ARDS, acute respiratory distress syndrome; CAP, community- acquired pneumonia; ULN, upper limit of normal; VTE, venous thromboembolism.
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DISCUSSION
Responses of the experts to the final survey suggested that 
the management of adult patients with ARDS should be the 
same, regardless of the aetiology, specifically in the presence 
or absence of a COVID-19 diagnosis. Furthermore, it was 
recommended that clinicians should broadly adhere to existing 
published guidelines for the management of ARDS for relevant 
evidence- based interventions.14 There was very little disagree-
ment between experts; the DI was significant (DI >1) only 
when addressing the appropriateness of diagnostic bronchos-
copy in patients with confirmed or suspected COVID-19. The 
appropriateness of routine bronchoscopy in the general ARDS 
population was uncertain. Fibre- optic bronchoscopy with bron-
choalveolar lavage was relatively safe historically, having been 
associated with infrequent complications in hypoxaemic patients 
with acute respiratory failure19 and a low risk of transmission of 
infection to healthcare workers.20 In a case series of intubated 
patients with COVID-19- related ARDS, the results of bronchos-
copy performed as clinically indicated, as opposed to routinely 
on admission (the survey question), were well tolerated and 
influenced decision- making around antimicrobial use in 50% of 
cases.21
Standard evidence- based management of ARDS according 
to guidelines centres around supportive strategies that aim to 
minimise VALI, which is a crucial determinant of outcome.22 
The impetus for treating COVID-19- related ARDS differently 
from ‘general’ ARDS arose partly from controversial observa-
tions suggesting that ARDS resulting from COVID-19 was a 
distinct entity.23 In a case series of 32 patients with COVID-19, a 
phenotype was described with relatively preserved lung compli-
ance and poor recruitability in response to an increase in PEEP.24 
The expert panel judged that five organ support strategies were 
appropriate for routine use in ARDS regardless of the aetiology. 
For all cases, protective mechanical ventilation using low tidal 
volumes and airway pressures, and a conservative fluid balance 
strategy were approved. For moderate and severe cases, prone 
positioning and the use of higher PEEP were deemed appro-
priate. These findings correlate with strong recommendations 
for protective ventilation and proning in the UK guidelines, 
whilst the other three strategies were suggested a weaker recom-
mendation reflecting the evidence base.
Despite a relatively weak evidence base in ARDS generally, 
but in accordance with clinical practice in several countries, for 
patients with severe ARDS meeting criteria from the CESAR 
study that have become standard,25 referral to an ECMO centre 
was deemed to be appropriate. Satisfactory outcomes of patients 
with COVID-19 who were supported with ECMO have been 
reported,26 in accordance with data from the H1N1 influenza 
A pandemic of 2009–2010.27 By contrast, there are fewer large 
studies demonstrating the safety and efficacy of APRV, and the 
experts were uncertain about the appropriateness of its use in all 
patients with ARDS.
Guidelines recommend the use of neuromuscular blockade 
(cisatracurium infusion) for the first 48 hours of invasive mechan-
ical ventilation in patients with moderate- severe ARDS.14 The 
expert panel thought the routine use of neuromuscular blockade 
to be of uncertain value both before and after the first 48 hours. 
This decision reflected the results of the recent Prevention and 
Early Treatment of Acute Lung Injury network’s ROSE study of 
early cisatracurium infusion plus heavy sedation versus a usual- 
care approach without routine neuromuscular blockade and 
with lighter sedation targets.28 The study was stopped at the 
second interim analysis for futility with 90- day mortality rates 
in the intervention and control groups of 42.5% and 42.8%, 
respectively. Recruitment manoeuvres were not addressed by the 
UK guideline development group, owing to difficulty in defining 
the intervention and a paucity of robust evidence, but their use 
was supported by the international guideline.15 Recent studies 
in moderate- severe ARDS have suggested potential harm asso-
ciated with high airway pressure (up to 60 cmH2O) recruitment 
manoeuvres, which may have influenced experts’ opinion that 
their use was inappropriate.29
Despite a plethora of conflicting guidance on the use of 
non- invasive ventilatory support in patients with COVID-19- 
related respiratory failure from the WHO, National Health 
Service England, British Thoracic Society, FICM/ICS/Royal 
College of Anaesthetists/Association of Anaesthetists and the 
Surviving Sepsis Campaign, the expert panel was unanimous 
in recommending no difference in the management regardless 
of the aetiology.8–12 The use of NIV was deemed inappropriate, 
which may reflect reported survival of patients supported with 
NIV compared with NHFO and conventional oxygen therapy: 
NIV was associated with a higher 90- day mortality in patients 
with acute hypoxic respiratory failure, possibly by exacerbating 
VALI.30 31 Similarly, the use of NIV compared with invasive 
mechanical ventilation was associated with a higher mortality 
in patients with moderately severe ARDS,32 consistent with the 
feeling that the use of non- invasive strategies should not delay 
tracheal intubation. Hence, the relevant survey questions stipu-
lated a limited trial of a non- invasive strategy lasting between 1 
and 4 hours, and the experts deemed that a failure to improve 
would indicate invasive mechanical ventilation and not an alter-
native non- invasive strategy. The experts were not invited to 
choose between non- invasive strategies and for lack of discrim-
inating evidence showed equipoise for the use of NHFO and 
CPAP, and the practise of awake proning.
One of the distinguishing clinical features of COVID-19 is the 
high prevalence of thromboembolic disease, frequently mani-
festing as pulmonary hypertension and increased dead space 
ventilation.33 Using a random- effects model, meta- analysis 
of 20 studies that enrolled 1988 patients with COVID-19 
rendered a weighted mean prevalence of venous thromboem-
bolism of 31.3% (95% CI: 24.3% to 39.2%).34 While standard 
prophylaxis was accepted as being appropriate for all seriously 
ill patients with COVID-19, there was equipoise from the panel 
for enhanced thromboprophylaxis (eg, double the recommended 
dose of low- molecular- weight heparin), full anticoagulation and 
the addition of antiplatelet agents. The panel judged that it 
was appropriate to anticoagulate fully a patient based on clin-
ical suspicion of venous thromboembolism, but was uncertain 
about relying on a single laboratory- derived test like D- dimer, 
which is in accordance with international guidelines.35 Similarly, 
for non- COVID-19 ARDS, the use of inhaled vasodilators (eg, 
nitric oxide) to manage refractory hypoxaemia was judged to be 
inappropriate, whereas there was uncertainty about their use in 
COVID-19 probably because the burden of pulmonary vascular 
disease outweighed potential adverse effects (an increased risk 
of renal failure), logistic challenges and the expense.36 While 
an evidence base is lacking, numerous case series have reported 
on the use of inhaled nitric oxide for COVID-19, and the 
Surviving Sepsis Campaign suggested a brief trial as a rescue 
therapy for severe hypoxia.12 National and international guide-
lines are increasingly suggesting enhanced thromboprophylaxis 
for critically ill patients with COVID-19. While full anticoag-
ulation and antiplatelet dose aspirin are proposed treatment 
options for the REMAP- CAP and RECOVERY adaptive design 
platform trials,37 38 our results suggest that trials of alternative 
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anticoagulation regimens may be complicated by a lack of 
equipoise.
It is axiomatic that despite active research dating back to the 
1960s, there are no effective disease- modifying therapies for the 
management of ARDS. The UK guidelines recommended that 
owing to a paucity of adequate clinical trials further research 
be carried out into the role of corticosteroids in the manage-
ment of ARDS, but no other drug treatments were considered.14 
Hence, the survey questions in this section addressed patients 
with COVID-19- related ARDS exclusively.
Following the recent H1N1 influenza A pandemic, the 
research community has been primed to take advantage of 
the unique potential for clinical trials presented by a global 
pandemic.39 Numerous studies have tested several interven-
tions in thousands of hospitalised patients with COVID-19. 
A meta- analysis of seven studies using corticosteroids in 1703 
patients with COVID-19 requiring varying degrees of respi-
ratory support from a minimum of supplemental oxygen 
showed a lower 28- day all- cause mortality in the group that 
had been given steroids.40 In this respect, severe COVID-19 
may differ from similar viral pneumonias causing ARDS. For 
example, a meta- analysis of observational studies in influenza 
suggested increased mortality with corticosteroid treatment.41 
The optimum drug, dose and timing of corticosteroid admin-
istration are not defined by existing studies. The experts were 
uncertain about the use of ‘late’ high- dose corticosteroids as 
well as other potential drug therapies that are still in clinical 
trials or for which the evidence is deemed to be equivocal. 
In the future, trials will probably select patient populations 
using laboratory tests for selected biomarkers that are paired 
with specific interventions to provide a personalised approach. 
For example, the procalcitonin assay may be used to curtail or 
initiate antibiotic therapy, circulating markers of inflammatory 
clotting cascade to modify anticoagulation regimens, and anal-
ysis of circulation cytokines and physiological parameters to 
select patients who are likely to respond to anti- inflammatory 
therapies that may be targeted monoclonal antibodies or 
pluripotent agents like statins.
One of the strengths of our study was the diversity of ARDS 
experts drawn from various UK centres and backgrounds with 
experience in managing patients with COVID-19 and ARDS. 
Conversely, the experts were exclusively UK- based and their 
opinions predominantly compared with the practice recom-
mended by the most comprehensive and recent guideline for 
the management of ARDS which is also from the UK. RAND 
methodology is validated as a guide to decision- making in 
the absence of a robust evidence base. While the expert panel 
was provided with up- to- date literature, it was not possible 
to determine the extent to which these findings influenced 
responses. Similarly, it was impossible for our scenarios to 
encompass all cases encountered in clinical practice, and some 
of the interventions (high vs low PEEP, recruitment manoeu-
vres, conservative fluid balance and autoimmune screen) were 
poorly defined, reflecting inconsistency in clinical trials and 
routine practice. The fact that three of the expert panel helped 
to design the original survey is likely to have introduced an 
element of bias; conversely, in accordance with RAND meth-
odology, the nature of the final questionnaire was changed 
from the original by the entire panel and moderator after the 
online meeting. We focused on selected management strat-
egies, including those covered in recent guidelines, to aid 
decision- making in ARDS in the context of COVID-19. Inev-
itably, some important areas of care were not covered, and 
combinations of strategies were not addressed. The outcomes 
should be considered an adjunct to multidisciplinary decision- 
making rather than a replacement. The RAND methodology 
asks experts to decide about the appropriateness of a given 
intervention regardless of the resource utilisation and without 
considering anything other than patient benefit. Pandemics 
highlight utilitarian considerations, for example, resources 
in a pandemic may be critically limited and it is imperative 
to protect health workers from contagion. This was perfectly 
exemplified by the use of non- invasive respiratory support 
during the COVID-19 crisis when there was a real risk of 
oxygen delivery failure in hospitals, infection of staff and 
other patients by aerosols, and the saturation of the capacity 
to care for patients requiring invasive mechanical ventilation. 
Finally, knowledge is evolving at an unprecedented rate such 
that it will be important and challenging to keep up with new 
developments.
In conclusion, we have provided guidance concerning the 
management of COVID-19- related ARDS during the pandemic. 
The expert panel recommended adhering to evidence- based 
supportive strategies for managing ARDS as they have been 
described in recent guidelines. Similarly, for supportive strate-
gies outside of existing guidelines, the recommendations were 
the same for ARDS regardless of whether it was associated 
with COVID-19 pneumonia. However, techniques for treating 
the distinct pathological features of COVID-19 have emerged 
thanks to powerful, methodologically innovative studies.
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